On July 6, CSPC Pharmaceutical rose 3.37% in regular trading, trading at HK$8.3/share, with turnover of HK$136 million. The stock continues to benefit from the company's recently announced landmark strategic collaboration with AstraZeneca.

Under the agreement, CSPC will leverage its proprietary siRNA drug discovery platform and extrahepatic targeted delivery platform to co-develop preclinical candidates for the treatment of renal diseases across two targets. CSPC received a $30 million upfront payment, with potential development milestone payments of up to $540 million and sales milestone payments of up to $1.2 billion, bringing the total deal value to approximately $1.77 billion. CSPC retains full rights to develop, manufacture, and commercialize one resulting candidate within China.

The deal's positive impact is compounded by multiple pipeline catalysts, including ADC drug SYS6043 receiving breakthrough therapy designation for platinum-resistant ovarian cancer, iron sucrose injection obtaining marketing approval, and the herpes zoster vaccine securing clinical trial approval in China.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)